HUAI-CHENG HUANGANN-LII CHENGCHUNG-WU LINSUNG-HSIN KUO2020-03-032020-03-0320130939-5555https://www.scopus.com/inward/record.uri?eid=2-s2.0-84878981524&doi=10.1007%2fs00277-012-1651-7&partnerID=40&md5=ce346305064630916af8ace24f4f1ce9https://scholars.lib.ntu.edu.tw/handle/123456789/468856[SDGs]SDG3carmustine; clarithromycin; cyclophosphamide; etoposide; folinic acid; methotrexate; methylprednisolone sodium succinate; prednisolone; rituximab; vincristine; adult; antibiotic therapy; brain radiation; case report; cerebrospinal fluid cytology; computer assisted tomography; diplopia; disease course; drug response; dysarthria; dysphagia; eyelid tumor; gait disorder; headache; hearing impairment; histopathology; human; large cell lymphoma; letter; male; malignant transformation; marginal zone lymphoma; neck pain; nuclear magnetic resonance imaging; orbit tumor; outcome assessment; primary central nervous system lymphoma; priority journal; ptosis; systemic therapy; tongue disease; tumor biopsy; tumor regression; upper eyelid; Adult; Antibodies, Monoclonal, Murine-Derived; Antineoplastic Combined Chemotherapy Protocols; Carmustine; Clarithromycin; Cranial Irradiation; Cyclophosphamide; Disease Progression; Etoposide; Humans; Immunophenotyping; Immunosuppressive Agents; Injections, Spinal; Lymphoma, B-Cell, Marginal Zone; Lymphoma, Large B-Cell, Diffuse; Male; Meningeal Neoplasms; Methotrexate; Methylprednisolone Hemisuccinate; Orbital Neoplasms; Prednisolone; Remission Induction; VincristinePrimary central nervous system diffuse large B cell lymphoma transformed from orbital mucosa-associated lymphoid tissue lymphoma: Complete response to combined intrathecal and systemic rituximabletter10.1007/s00277-012-1651-7232424762-s2.0-84878981524